FUB-PB-22

Summary

FUB-PB-22, or QUFUBIC, is a synthetic cannabinoid rooted in the indole structure. It exhibits potent agonistic activity on the CB1 receptor and has been made available for purchase on the internet as a designer drug.

Identifiers

IUPAC name
CAS Number	1800098-36-5
PubChem CID	91936864
ChemSpider	29763736
UNII	DS46154N3F
Chemical and physical data
Formula	C25H17FN2O2
Molar mass	396.421 g·mol−1

Pharmacology

FUB-PB-22 functions as a complete agonist, demonstrating exceptional binding affinity with a mere 0.386nM at CB1 and 0.478nM at CB2 cannabinoid receptors.

Legal status

In terms of legal classification, FUB-PB-22 is categorized as an Anlage II controlled substance in Germany. Furthermore, it was officially scheduled in Japan in July 2014. Notably, as of October 2015, FUB-PB-22 is also recognized as a controlled substance in China. It is important to mention that this substance is banned in Sweden as well.

FAQ

• What is FUB-PB-22?
• FUB-PB-22 is a synthetic cannabinoid known for its high affinity for CB1 and CB2 receptors, part of the endocannabinoid system. It’s often used as a recreational drug.
• How does FUB-PB-22 affect the body?
• FUB-PB-22 binds to cannabinoid receptors, altering perception, relaxation, and other psychoactive effects. However, it can also lead to anxiety and other adverse effects.
• Is FUB-PB-22 legal?
• The legal status of FUB-PB-22 varies by country. It is classified as a controlled substance in some nations, such as Germany, Japan, and China, and it is banned in Sweden.
• What are the potential risks of using FUB-PB-22?
• FUB-PB-22 and similar synthetic cannabinoids have been linked to various health risks, including addiction potential, cardiovascular problems, and psychological side effects. Long-term effects are not well understood due to limited research.
• Is it safe to use FUB-PB-22?
• FUB-PB-22 is not considered safe due to the lack of research on its long-term effects and potential health risks. It is advised to avoid its use.
• Can FUB-PB-22 be detected in drug tests?
• FUB-PB-22 and similar synthetic cannabinoids may or may not be detected in standard drug tests. Specific tests are required to see these substances, and their inclusion in routine drug screenings may vary.
• What should I do if I encounter FUB-PB-22 or similar substances?
• If you come across FUB-PB-22 or related synthetic cannabinoids, it’s advisable to avoid them and report any suspicious substances to the relevant authorities to protect public health and safety.
• Is FUB-PB-22 commonly found in recreational products?
• FUB-PB-22 has been reported in designer drugs and synthetic cannabinoid products marketed as alternatives to traditional cannabis. However, its presence in such products can vary.
• Is there medical use for FUB-PB-22?
• FUB-PB-22 is not approved for medical use, and its recreational use is discouraged due to its potential health risks.
• Where can I find more information about FUB-PB-22?
• It’s essential to stay informed about the legal status and potential health risks associated with FUB-PB-22. Consult reputable sources and seek guidance from healthcare professionals if needed.

References

1. “FUB-PB-22” is a synthetic compound that gained attention within the scientific community. The information on this compound is archived by the Southern Association of Forensic Scientists, originating from May 27, 2015, and retrieved on July 23, 2015.
2. In February 2015, Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, and Hakamatsuka T published a significant discovery in the realm of forensic toxicology. Their research, titled “N-OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products,” was featured in the 33rd volume, issue 2 of Forensic Toxicology. The study unveiled intriguing insights, spanning pages 244 to 259, and is accessible via the DOI reference 10.1007/s11419-015-0268-7. The article is also available through PMC (PubMed Central) with reference PMC 4525202, and the PMID (PubMed ID) is 26257833.
3. Hess C, Schoeder CT, Pillaiyar T, Madea B, and Müller CE conducted a comprehensive study on synthetic cannabinoids in their research published on July 1, 2016. The study, titled “Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice,” is part of the 34th volume, issue 2 of Forensic Toxicology, with pages 329 to 343. This valuable research can be accessed via the DOI reference 10.1007/s11419-016-0320-2. It is also available on PMC (PubMed Central) with reference PMC 4929166, and the PMID (PubMed ID) is 27429655.
4. The China Food and Drug Administration released a notice in Chinese, titled “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” (translation: “Notice on the issuance of the ‘Measures for the Administration of Non-Medicinal Narcotic Drugs and Psychotropic Drugs'”). This announcement was made on September 27, 2015, and its archive is dated October 1, 2015, with the retrieval date being the same.
5. On May 28, 2014, the Swedish agency Folkhälsomyndigheten released information indicating that “Cannabinoider föreslås bli klassificerade som hälsofarlig vara” (translation: “Cannabinoids are proposed to be classified as a health-hazardous product”). This information was retrieved on July 23, 2015.